Anneke C. J. Ammerlaan

Author

Also Known As

A C J Ammerlaan, A. C. J. Ammerlaan, Anneke Ammerlaan, Anneke C. J. Ammerlaan, Anneke C.J. Ammerlaan

Publications

258

Citations

H-Index

Concepts

All Affiliations

Anneke C. J. Ammerlaan is an author at Sheba Medical Center specializing in clinical genetics, genetics, and cancer research.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	74
2	Pathology	1	1	74
3	Clinical Genetics	1	1	74
4	Developmental Biology	1	1	74
5	Genetics	1	1	74

Anneke C. J. Ammerlaan

Publications

238

Citations

H-Index

Page 1

	Year	Citations
A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study) Erica Brivio, Franco Locatelli, Marta López‐Yurda, Blood	2020	88
Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome Anneke C. J. Ammerlaan, Abdelhay Ararou, M.P.W.A. Houben, British Journal of Cancer Developmental BiologySomatic VariantMendelian DisorderGenetic DisorderMedicine	2007	74
Localization of a putative low‐penetrance ependymoma susceptibility locus to 22q11 using a chromosome 22 tiling‐path genomic microarray Anneke C. J. Ammerlaan, Cecilia de Bustos, Abdelhay Ararou, Genes Chromosomes and Cancer	2005	28
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan, Haematologica	2024	17
A Phase II Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of the ITCC-059 Study Erica Brivio, Franco Locatelli, Adriana Thano, Blood	2020	16
Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation Anneke C. J. Ammerlaan, M.P.W.A. Houben, Cees Tijssen, Child s Nervous System	2008	15

Page 1